Drug Trial Radar · NCT05040490
Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography
Last checked: Nov 20, 2026Latest source record: Sep 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
414
Planned (sponsor's estimate)
Start
Aug 31, 2021
Primary completion
Jul 2022
Study completion Sep 2022
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aims to compare the incidence of postoperative residual curarisation (PORC) and postoperative pulmonary complications (PPCs) in the SUG and NEO group by means of diaphragm ultrasonography and LUS, so as to conclude whether SUG can outperform NEO in preventing occurrence of PORC and PPCs.
Conditions
- Postoperative Pulmonary Complications
Interventions
sugammadex as reversal drugsDrug
use sugammadex to reverse neuromuscular blockade
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of postoperative pulmonary complicationsTime frame: 30 days after surgery
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.